טוען...
Adaptive Reprogramming of De Novo Pyrimidine Synthesis is a Metabolic Vulnerability in Triple-Negative Breast Cancer
Chemotherapy resistance is a major barrier to the treatment of triple-negative breast cancer and strategies to circumvent resistance are required. Using in vitro and in vivo metabolic profiling of triple-negative breast cancer cells, we show that an increase in the abundance of pyrimidine nucleotide...
שמור ב:
| הוצא לאור ב: | Cancer Discov |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5380483/ https://ncbi.nlm.nih.gov/pubmed/28255083 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0611 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|